PMID- 15675482
OWN - NLM
STAT- MEDLINE
DCOM- 20050210
LR  - 20191109
IS  - 1120-009X (Print)
IS  - 1120-009X (Linking)
VI  - 16 Suppl 5
DP  - 2004 Nov
TI  - TNFa-based isolated hyperthermic limb perfusion (HILP) in the treatment of limb 
      recurrent melanoma: update 16 years after its first clinical application.
PG  - 62-5
AB  - Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFalpha) 
      and interferon gamma (IFNgamma) was pioneered by Lienard and Lejeune in 1988. 
      TNFalpha was empirically employed at a dosage of 3-4 mg that is ten times the 
      systemic maximum tolerated dose (MTD). Sixteen years after its first clinical 
      application more than 300 patients have been treated and some clarifications can 
      be made regarding three major questions: the real role of IFNgamma, the TNFalpha 
      dose and eligibility criteria for patient selection. A randomized phase II study 
      has demonstrated that IFNgamma does not increase significantly the efficacy but 
      does increase side-effects. Experimental and clinical results seem to indicate 
      that patients with bulky melanoma disease can really benefit from TNFalpha HILP 
      carried out with only 1 mg.
FAU - Di Filippo, F
AU  - Di Filippo F
AD  - Regina Elena National Cancer Institute, Rome, Italy. difilippo@ifo.it
FAU - Cavaliere, F
AU  - Cavaliere F
FAU - Garinei, R
AU  - Garinei R
FAU - Anza, M
AU  - Anza M
FAU - Di Angelo, P
AU  - Di Angelo P
FAU - Psaila, A
AU  - Psaila A
FAU - Piarulli, L
AU  - Piarulli L
FAU - Callopoli, A
AU  - Callopoli A
FAU - Bruno, P
AU  - Bruno P
FAU - Di Filippo, S
AU  - Di Filippo S
FAU - Priore, F
AU  - Priore F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Chemotherapy, Cancer, Regional Perfusion/*methods
MH  - Extremities
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Interferon-gamma/pharmacology
MH  - Maximum Tolerated Dose
MH  - Melanoma/*drug therapy
MH  - Recurrence
MH  - Tumor Necrosis Factor-alpha/*administration & dosage
EDAT- 2005/01/29 09:00
MHDA- 2005/02/11 09:00
CRDT- 2005/01/29 09:00
PHST- 2005/01/29 09:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2005/01/29 09:00 [entrez]
AID - 10.1080/1120009x.2004.11782388 [doi]
PST - ppublish
SO  - J Chemother. 2004 Nov;16 Suppl 5:62-5. doi: 10.1080/1120009x.2004.11782388.